Superworth

Medpace price to free cash flow MEDP

Market value divided by free cash flow over the last twelve months, since 2017.

Today, Nov 2, 2026
25.6×
9-year median
20.3×
Against its 9-year history
85th
percentile: 0 is its lowest day, 100 its highest
9-year range
12.0× to 33.3×
Peer median
34.3×

Medpace's price to free cash flow is 25.6× as of Nov 2, 2026.

That is above its 9-year median of 20.3×, higher than on 85% of days in the last 9 years.

Over that time it ranged from 12.0× in May 2018 to 33.3× in Feb 2021.

The median for 10 diagnostics and research stocks of a similar size is 34.3×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far25.6×16.5×26.4×
202523.6×15.3×25.8×
202419.8×18.0×31.7×
202324.9×15.5×25.7×
202223.1×18.0×25.2×
202128.9×24.6×33.3×
202027.5×13.1×27.7×
201917.9×12.7×19.3×
201814.2×12.0×18.9×
201716.2×14.0×16.6×

Against its peers

Companies in Medical - Diagnostics & Research nearest Medpace's size, closest first, today.

CompanyPrice to free cash flow
MEDPMedpace25.6×
RVTYRevvity30.3×
DGXQuest Diagnostics20.0×
LHLabcorp25.0×
BIOBio-Rad Laboratories27.7×
MTDMettler-Toledo International39.6×
ILMNIllumina38.4×
CAICaris Life Sciences73.2×
IQVIQVIA19.4×
WATWaters117×
AAgilent Technologies39.1×
Peer median34.3×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Medpace

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.